Can Oral Gildeuretinol Slow Advanced Macular Degeneration?
Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.
By
Andrea Surnit
July 20, 2026
Clinical Scorecard: Can Oral Gildeuretinol Slow Advanced Macular Degeneration?
At a Glance
Category Detail
Condition Age-related macular degeneration Key Mechanisms Oral gildeuretinol acetate Target Population Patients aged 60 years or older with geographic atrophy secondary to age-related macular degeneration Care Setting Phase 2/3 clinical trial
Key Highlights
Primary endpoint of geographic atrophy lesion growth not met 13% reduction in lesion growth with gildeuretinol compared to placebo Exploratory outcomes favored gildeuretinol in visual acuity and quality of life Safety profile similar between treatment groups with no new safety signals Study enrollment curtailed due to COVID-19 pandemic Guideline-Based Recommendations
Diagnosis
Geographic atrophy assessed by fundus autofluorescence Management
Consider exploratory findings for further evaluation in larger trials Monitoring & Follow-up
Monitor visual acuity and quality of life measures Risks
Treatment-emergent adverse events occurred in 72% of gildeuretinol patients Patient & Prescribing Data
198 participants aged 60 years or older
Gildeuretinol acetate showed exploratory benefits but did not meet primary efficacy endpoint
Clinical Best Practices
Interpret exploratory findings with caution due to primary endpoint not being met Consider larger, adequately powered studies for confirmation of exploratory outcomes Related Resources & Content
